Horizon Therapeutics Public Limited Company

Financial performance has remained strong, with revenue growing from $925.36M in Q3 2022 to $944.96M in Q2 2023. Gross profit continued to perform well, with margins at 77% in the latest quarter. Operating income reached $142.84M in Q2 2023, holding a steady 15% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $241.31M. Net income rose to $127.07M, keeping EPS at $0.56. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.